Ping An Biomedical shares surge 38.0% after-hours after securing strategic investments from 58 Group, Amiba Capital, and Magcloud Group executives.

Ping An Biomedical surged 37.95% in after-hours trading following the announcement of a strategic investment from prominent industry figures, including 58 Group’s Yao Jinbo, Amiba Capital’s Wang Donghui, and Magcloud Group’s Li Daxue. These investors, known for their expertise in technology, venture capital, and large-scale operations, underscored confidence in Ping An Bio’s biopharmaceutical R&D capabilities, innovation roadmap, and long-term growth potential. The investment aligns with the company’s “technology empowering healthcare” strategy, aiming to.